20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Candel Therapeutics Inc (CADL) operates in the BIOTECHNOLOGY industry and is headquartered in Needham, United States with about 55 employees. Its market capitalization is roughly $830 million. In the fiscal year ended 2025-12-31, CADL reported $0M in revenue and ($38M) in net income.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | ($1M) | ($1M) | ($24M) | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | -77354.8% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($72M) | ($48M) | ($33M) | ($38M) | ($35M) | ($26M) | ($14M) | ($9M) |
| Operating Margin % | — | — | — | -123841.9% | -27739.2% | -20580.8% | -11048.0% | -7229.6% |
| Net Income | ($89M) | ($38M) | ($55M) | ($38M) | ($19M) | ($36M) | ($18M) | ($8M) |
| Net Margin % | — | — | — | -122383.9% | -15035.2% | -28899.2% | -14144.0% | -6592.0% |
| EBITDA | ($83M) | ($35M) | ($52M) | ($34M) | ($16M) | ($36M) | ($13M) | ($8M) |
| Earnings Per Share (EPS) | $-1.41 | $-0.72 | $-1.74 | $-1.31 | $-0.65 | $-1.91 | $-0.94 | $-0.44 |
| Shares Outstanding (M) | 74M | 53M | 32M | 29M | 29M | 19M | 19M | 19M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $1M | $0M |
| Gross Profit | — | $0M | $0M | $0M | $0M | $0M | $0M | ($5M) |
| Gross Margin % | — | — | — | — | — | — | -24.5% | — |
| Operating Income (EBIT) | ($27M) | ($16M) | ($16M) | ($13M) | ($11M) | ($8M) | ($8M) | ($9M) |
| Operating Margin % | — | — | — | — | — | — | -814.1% | — |
| Net Income | ($39M) | ($9M) | ($29M) | ($11M) | ($5M) | $7M | ($14M) | ($11M) |
| Net Margin % | — | — | — | — | — | — | -1407.3% | — |
| EBITDA | ($37M) | ($7M) | ($28M) | ($11M) | ($4M) | $8M | ($13M) | ($10M) |
| Earnings Per Share (EPS) | $-0.52 | $-0.14 | $-0.54 | $-0.21 | $-0.09 | $0.23 | $-0.40 | $-0.33 |
| Shares Outstanding (M) | 74M | 62M | 55M | 55M | 51M | 32M | 36M | 32M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($56M) | ($38M) | ($27M) | ($34M) | ($31M) | ($22M) | ($9M) | ($5M) |
| Capital Expenditures (CapEx) | $1M | $1M | $0M | $0M | $1M | $2M | $1M | $0M |
| Free Cash Flow (FCF) | ($57M) | ($39M) | ($27M) | ($35M) | ($33M) | ($24M) | ($11M) | ($5M) |
| FCF Margin % | — | — | — | -111938.7% | -26172.8% | -19242.4% | -8437.6% | -4268.8% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($17M) | ($18M) | ($11M) | ($10M) | ($9M) | ($9M) | ($6M) | ($7M) |
| Capital Expenditures (CapEx) | $0M | $1M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($17M) | ($19M) | ($11M) | ($10M) | ($9M) | ($9M) | ($6M) | ($7M) |
| FCF Margin % | — | — | — | — | — | — | -581.7% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $208M | $125M | $107M | $41M | $79M | $89M | $38M | $46M |
| Cash & Cash Equivalents | $202M | $120M | $103M | $35M | $70M | $83M | $35M | $5M |
| Total Liabilities | $82M | $73M | $41M | $28M | $31M | $25M | $62M | $54M |
| Total Debt (Short + Long-Term) | $48M | $48M | $13M | $22M | $21M | $1M | $1M | $0M |
| Total Shareholders' Equity | $126M | $52M | $66M | $13M | $48M | $64M | ($24M) | ($8M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CADL viewer.
About TickerBase · Data methodology & sources · Privacy · Terms